Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8786076 | PMC |
http://dx.doi.org/10.1164/rccm.202108-2002ED | DOI Listing |
Am Soc Clin Oncol Educ Book
January 2025
Division of Oncology, Department of Medicine, University of Washington, Seattle, WA.
The growing sophistication of tumor molecular profiling has helped to slowly transition oncologic care toward a more personalized approach in different tumor types, including in bladder cancer. The National Comprehensive Cancer Network recommends that all patients with stage IVA and stage IVB urothelial carcinoma have molecular analysis that integrates at least testing to help facilitate the selection of future therapeutic options. Sequencing of tumor-derived tissue is the mainstay to obtain this genomic testing, but as in other cancers, there has been extensive research into the integration of liquid biopsies in longitudinal management.
View Article and Find Full Text PDFJCI Insight
January 2025
Medical Oncology Department, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, Netherlands.
Background: Previously, we demonstrated that changes in circulating tumor DNA (ctDNA) are promising biomarkers for early response prediction (ERP) to immune checkpoint inhibitors (ICI) in metastatic urothelial cancer (mUC). In this study, we investigated the value of whole blood immunotranscriptomics for ERP-ICI and integrated both biomarkers into a multimodal model to boost accuracy.
Methods: Blood samples of 93 patients were collected at baseline and after 2-6 weeks of ICI for ctDNA (N=88) and immunotranscriptome (N=79) analyses.
BMJ Nutr Prev Health
December 2024
Laboratory of Toxicology and Forensic Sciences, Medical School of the University of Crete, Crete, Greece.
Background: Non-communicable diseases (NCDs), known as chronic diseases, significantly impact patients' quality of life (QoL) and increase medical expenses. The majority of risk factors are modifiable, and metabolomics has been suggested as a promising strategy for their evaluation, though real-world data are scarce. This study evaluated the QoL improvement and cost-effectiveness of a metabolomics-based treatment for NCDs, aiming to restore metabolic dysfunctions and nutritional deficiencies.
View Article and Find Full Text PDFACS Appl Nano Mater
January 2025
Atomic Manipulation and Spectroscopy Group (AMS), Catalan Institute of Nanoscience and Nanotechnology (ICN2), CSIC and BIST, Bellaterra, 08193 Barcelona, Spain.
Despite the outstanding progress in photonic sensor devices, a major limitation for its application as label-free biosensors for biomedical analysis lies in the surface biofunctionalization step, that is, the reliable immobilization of the biorecognition element onto the sensor surface. Here, we report the integration of bottom-up synthesized nanoporous graphene onto bimodal waveguide interferometric biosensors as an atomically precise biofunctionalization scaffold. This combination leverages the high sensitivity of bimodal waveguide interferometers and the large functional surface area of nanoporous graphene to create highly sensitive, selective, and robust biosensors for the direct immunoassay detection of C-reactive protein (CRP), an inflammatory biomarker widely used in the clinical diagnosis of infections and sepsis.
View Article and Find Full Text PDFFront Immunol
January 2025
Integrative Immunobiology Department, Duke University, Durham, NC, United States.
Introduction: The regulation of expression during T-cell development and immune responses is essential for proper lineage commitment and function in the periphery. However, the mechanisms of genetic and epigenetic regulation are complex, and their interplay not entirely understood. Previously, we demonstrated the need for CD4 upregulation during positive selection to ensure faithful commitment of MHC-II-restricted T cells to the CD4 lineage.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!